NDA 018671 · Cardinal Health 418
Sodium Iodide I 123
Sodium Iodide I-123 · Oral
Last checked: Nov 19, 2026Latest source record: Jun 13, 2008 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1982
May 27, 1982
Approved uses
1
Original approval plus efficacy supplements
Registered trials
28
5 Phase 3, 3 recruiting
FAERS reports
940
896 serious, 45 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 17, 2018.
INDICATION AND USE Administration of Sodium Iodide I 123 is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 27, 1982 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
- SODIUM IODIDE I 123 · SODIUM IODIDE I-123 200uCi · CAPSULE, ORAL · Prescription · TE AA
- SODIUM IODIDE I 123 · SODIUM IODIDE I-123 400uCi · CAPSULE, ORAL · Discontinued
- SODIUM IODIDE I 123 · SODIUM IODIDE I-123 100uCi · CAPSULE, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Iodide I-123" as an intervention, any sponsor and status, largest first.
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Pivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03126916 · 750 participants (planned) · Start May 14, 2018 · Primary completion Sep 30, 2030
Drug: Busulfan; Carboplatin and 13 more · For: Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 164 sites in all
- Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular DiseasePivotal-lookingCompleted
GE HealthcareIndustry
NCT00126425 · 587 participants · Start Jul 2005 · Primary completion Jul 2008
Drug: 123I-mIBG (meta-iodobenzylguanidine) · For: Heart Failure, Congestive
Sites: Princeton, New Jersey
- Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid CancerPivotal-lookingStatus unknown
National Cancer Center, KoreaGovernment (non-federal)
NCT02418247 · 556 participants (planned) · Start May 2013 · Primary completion Dec 2017
Drug: I131; I123 · For: Thyroid Neoplasms
Sites: Daejun, South Korea; Goyang, South Korea; Seoul, South Korea · 5 sites in all
- Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular DiseasePivotal-lookingCompleted
GE HealthcareIndustry
NCT00126438 · 515 participants · Start Jul 2005 · Primary completion Jul 2008
Drug: 123I-mIBG (meta-iodobenzylguanidine) · For: Heart Failure, Congestive
Sites: Princeton, New Jersey
- DaTSCAN Imaging in Aging and Neurodegenerative DiseaseEnrolling by invitation
Mayo ClinicAcademic, hospital or other
NCT01453127 · 500 participants (planned) · Start Oct 2011 · Primary completion Dec 2026
Drug: I-123 Ioflupane solution injection prior to SPECT scan (DaTscan) · For: Dementia; Parkinsonism; Mild Cognitive Impairment and 1 more
Sites: Rochester, Minnesota
- International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical DevicePivotal-lookingTerminated
GE HealthcareIndustry
NCT02656329 · 395 participants · Start Dec 30, 2015 · Primary completion May 4, 2018
Drug: Iobenguane I -123 Injection; Thyroid blocking and 1 more · For: Heart Failure
Sites: Birmingham, Alabama; Bakersfield, California; La Mesa, California · 94 sites in all
- Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK InhibitionStatus unknown
University Hospital, EssenAcademic, hospital or other
NCT04619316 · 70 participants (planned) · Start Feb 5, 2018 · Primary completion Dec 31, 2024
Drug: Trametinib 2 MG [Mekinist]; Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar] · For: Metastatic Thyroid Cancer
Sites: Essen, Germany
GE HealthcareIndustry
NCT01936649 · 63 participants · Start Aug 2013 · Primary completion Feb 2014
Drug: AdreView (Iobenguane I 123 Injection) · For: Heart Failure (HF); Ventricular Dysfunction, Left
Sites: Princeton, New Jersey
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypothyroidism384
- endocrine ophthalmopathy36
- treatment failure26
- acute myeloid leukaemia24
- dacryostenosis acquired24
- parathyroid tumour benign21
- abortion spontaneous20
- hyperthyroidism20
- hyperparathyroidism19
- lacrimation increased19
- breast cancer17
- maternal exposure during pregnancy17
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 33 |
| 2008 | 76 |
| 2009 | 56 |
| 2010 | 56 |
| 2011 | 263 |
| 2012 | 173 |
| 2013 | 82 |
| 2014 | 14 |
| 2015 | 17 |
| 2016 | 13 |
| 2017 | 5 |
| 2018 | 26 |
| 2019 | 48 |
| 2020 | 13 |
| 2021 | 48 |
| 2022 | 8 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Cardinal Health 418
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.